GNOM


Genomics & Biotechnology ETF

Fund Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Fund Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Why GNOM?

High Growth Potential

GNOM enables investors to access high growth potential through companies that are positioned to benefit from further advances in the field of genomic science.

Targeted Exposure

GNOM provides access to emerging areas within the Health Care Sector at the intersection of science and technology.

ETF Efficiency

In a single trade, GNOM delivers access to dozens of companies with exposure to the genomics theme.

Fund Details As of 9/25/20

Key Facts

Ticker GNOM
Inception Date 4/5/19
CUSIP 37954Y434
ISIN US37954Y4347
Bloomberg Index Ticker SOLGNOM
Primary Exchange Nasdaq
Number of Holdings 40

Stats & Fees

Net Assets $60,221,902
NAV $17.71
Shares Outstanding 3,400,000
Total Expense Ratio 0.50%

Distributions

30-Day SEC Yield N/A
Distribution Frequency Semi-Annually

Fund Prices As of 9/25/20

NAV Price
Net Asset Value $17.71 Closing Price $17.78
Daily Change $0.42 2.40% Daily Change $0.45 2.57%

Performance History

Cumulative %

Data as of month-end (8/31/20)

Fund NAV Closing Price Index
Year-to-Date 14.25% 14.21% 14.64%
1 Month 1.14% 1.08% 1.19%
3 Months 7.81% 8.06% 7.99%
6 Months 23.61% 23.20% 23.95%
Since Inception 16.49% 18.93% 17.48%

Avg Annualized %

Data as of month-end (8/31/20)

Fund NAV Closing Price Index
1 Year 30.02% 30.12% 30.83%
Since Inception 11.50% 13.16% 12.12%

Avg Annualized %

Data as of quarter-end (6/30/20)

Fund NAV Closing Price Index
1 Year 15.99% 16.07% 16.77%
Since Inception 11.86% 13.54% 12.53%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized Return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Fund Characteristics As of 9/26/20

Return on Equity -21.90%
Weighted Avg. Market Cap 8,313 M
2019 2020
Price-to-earnings -19.61 -32.40
Price-to-book value 6.38 8.01

Source: AltaVista Research, LLC

Fund Risk Stats As of 9/26/20

Versus Beta
S&P 500 1.10
MSCI EAFE 1.11
MSCI Emg. Mkts 0.83
Standard Deviation 33.90%

Source: AltaVista Research, LLC

Sector Breakdown As of 8/31/20

% of Net Assets
Health Care 96.8
Industrials 3.0
Other/Cash 0.2

Source: AltaVista Research, LLC

Country Breakdown As of 8/31/20

% of Net Assets
United States 82.2
Netherlands 6.4
Switzerland 5.8
China 3.0
Japan 1.9
Singapore 0.5
Other/Cash 0.2

Source: AltaVista Research, LLC

Top 10 Holdings As of 9/25/20

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
7.93 NVTA INVITAE CORP BVVCNT1 44.67 106,907 4,775,535.69
6.21 NTRA NATERA INC BYQRG48 68.62 54,496 3,739,515.52
5.26 CRSP CRISPR THERAPEUTICS AG BDHF4K6 84.09 37,671 3,167,754.39
4.24 A AGILENT TECHNOLOGIES INC 2520153 97.69 26,145 2,554,105.05
4.15 RARE ULTRAGENYX PHARM BJ62Z18 82.07 30,453 2,499,277.71
4.11 SRPT SAREPTA THERAPEUTICS INC B8DPDT7 144.00 17,190 2,475,360.00
4.09 BPMC BLUEPRINT MEDICINES CORP BWY52P3 88.00 28,019 2,465,672.00
4.04 QGEN QIAGEN N.V. BYXS688 51.92 46,830 2,431,413.60
3.97 ARWR ARROWHEAD PHARMA BYQBFJ8 44.92 53,206 2,389,747.49
3.35 BLUE BLUEBIRD BIO INC BBFL7S1 57.04 35,365 2,017,219.60
Holdings are subject to change.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. The closing price is the Mid-Point between the Bid and Ask price as of the close of exchange. Closing price returns do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.